- Details
- Description
-
Packaging Size30t/bottle
-
Strength60mg&80mg&100mg
-
CompositonResmetirom
-
TreatmentNonalcoholic Steatohepatitis
-
FormTablet
-
BrandLuciRes
-
Quantity Unit60mg*30T/Box&80mg*30T/Box&100mg*30T/Box
-
ManufacturerLucius Pharmaceuticals (Lao) Co.,Ltd
About Resmetirom
Resmetirom is a medication used for the treatment of noncirrhotic nonalcoholic steatohepatitis. It is a thyroid hormone receptor beta (NR1A2) agonist.
Nonalcoholic Steatohepatitis
Indicated in conjunction with diet and exercise for treatment of adults with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis)
Dosage is based on actual body weight
<100 kg: 80 mg PO qDay
≥100 kg: 100 mg PO qDay
Dosage Modifications
Dosage modifications for CYP2C8 inhibitors
- Strong CYP2C8 inhibitors (eg, gemfibrozil): Not recommended
-
Moderate CYP2C8 inhibitors (eg, clopidogrel)
- <100 kg: Reduce to 60 mg PO qDay
- ≥100 kg: Reduce to 80 mg PO qDay
Renal impairment
- Mild or moderate (CrCl ≥30 mL/min): No dosage adjustment necessary
- Severe (CrCl <30 mL/min): Not studied
Hepatic impairment
- Mild (Child-Pugh A): No dosage adjustment necessary
- Moderate or severe (Child-Pugh B or C): May increase resmetirom plasma concentrations and risk of resmetirom adverse reactions
- Decompensated cirrhosis (consistent with moderate to severe hepatic impairment): Avoid use
- NASH cirrhosis: Safety and efficacy not established
Dosing Considerations
Limitation of use: Avoid use in patients with decompensated cirrhosis
